BioMarin Pharmaceutical Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Revenues of $1,820 million to $1,880 million against $1,790 million to $1,880 million as announced earlier. GAAP Net Loss of $85 million to $45 million against $110 million to $60 million as announced earlier.